NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

InflaRx N.V. Common Stock (IFRX) Stock Analysis

InflaRx N.V. Common Stock (IFRX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

IFRX

$1.55

+$0.01 (+0.65%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IFRX with… →

IFRX Key Statistics

As of Oct 21, 2026
Trading
Open
$1.55
Previous Close
$1.54
Day's Range
1.54–1.61
52-Week Range
0.80–2.95
Volume
701.35K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.61
Valuation
Market Cap
$228.42M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.58
Financials (FY)
Revenue (FY)
$29.33K−82.31%
Net Income (FY)
−$45.63M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
147.37M
1-Year Return
+13.97%
Dividend and dates
Earnings Date
November 9, 2026estimated
Avg Volume
793.79K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, IFRX closed at $1.55, +13.97% over 1 year.

InflaRx N.V. Common Stock (IFRX) has a market capitalization of $228.42M.

In fiscal 2025, IFRX reported revenue of $29.33K.

IFRX Stock Return by Calendar Year

InflaRx N.V. Common Stock (IFRX) return since Nov 2017: what $10,000 became

1 year
$10,000 $11,397
+13.97%
5 years
$10,000 $5,576
−44.24%
Since Nov 2017
$10,000 $1,033
−89.67%

If you had invested $10,000 in InflaRx N.V. Common Stock (IFRX) at the close on November 7, 2017, the earliest close on record here, it would have been worth $1,033 at the close on October 21, 2026: −89.67% in total, −22.39% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+53.47%
2025−59.11%
2024+51.53%
2023−47.42%
2022−34.87%
2021−5.37%
2020+27.02%
2019−89.11%
2018+73.60%
2017 (partial year)+39.67%

As of October 21, 2026.

IFRX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$29.33K−$45.63M−155,582.1%
2024$165.79K−$46.06M−27,785.0%
2023$63.09K−$42.67M−67,630.7%
2022$0.00−$29.48M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$29.33K−$7.24M−$48.26M−$45.63M−155,582.1%
2024$165.79K−$3.15M−$52.91M−$46.06M−27,785.0%
2023$63.09K−$469.17K−$44.59M−$42.67M−67,630.7%
2022$0.00$0.00−$32.24M−$29.48M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

InflaRx N.V. Common Stock (IFRX) carries a market capitalisation of $228.42M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 65.

The 52-week range on file runs from $0.80 to $2.95. The most recent close on file for IFRX is $1.55, dated October 21, 2026. That is +$0.01 (+0.65%) against the previous close. The latest close sits 94.24% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $29.33K. That is −82.31% against the prior fiscal year, when revenue was $165.79K. The same year closed with a net loss of $45.63M. Trailing earnings per share are −0.58.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $29.33K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is 2.61. Annualized volatility over the trailing 9 years is 103.47%. The trailing one-year total return is +13.97%. Across 5 years the annualized return works out at −11.03%.

Growth & Income

No dividend is on file for IFRX.

So far in 2026 the total return is +53.47%. The strongest complete calendar year on file is 2018 at +73.60%; the weakest is 2019 at −89.11%. Of the 8 complete calendar years on file, 3 finished higher.

Peer Comparison

InflaRx N.V. Common Stock (IFRX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
InflaRx N.V. Common Stock IFRX $228.42M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. InflaRx N.V. Common Stock has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About InflaRx N.V. Common Stock

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.

Visit website →